Generic Name and Formulations:
Amoxapine 25mg, 50mg, 100mg, 150mg; tabs.
Indications for Amoxapine:
Depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. Depression accompanied by anxiety or agitation.
Initially 50mg 2–3 times daily; may increase to 100mg 2–3 times daily by the end of the first week. May increase above 300mg/day if dose has been ineffective for a period of at least 2 weeks. Maintenance: when effective dosage established, may give as single dose at bedtime (max 300mg). Elderly: initially 25mg 2–3 times daily; may increase by the end of the first week to 50mg 2–3 times daily. May increase carefully up to 300mg/day if necessary.
Within 14 days of MAOIs. During acute recovery phase following MI.
Monitor for clinical worsening, suicidality, and unusual changes in behavior, esp. during initial few months of treatment and during dose changes. Screen for bipolar disorder prior to initiating therapy. Urinary retention. Angle-closure glaucoma. Increased intraocular pressure. Cardiovascular disorders (monitor closely). Seizure disorders. Discontinue if rash, fever, tardive dyskinesia or neuroleptic malignant syndrome develop. Write ℞ for smallest practical amount. Pregnancy (Cat.C). Nursing mothers.
During or within 5 weeks of fluoxetine. Hyperpyretic crises, severe convulsions, and death with MAOIs (see Contraindications). Potentiates alcohol, barbiturates, other CNS depressants. Paralytic ileus with anticholinergics. Monitor serum levels with CYP450 2D6 inhibitors (eg, quinidine, cimetidine, phenothiazines, propafenone, flecainide, others: see literature). Caution with concomitant electroshock therapy.
Drowsiness, dry mouth, constipation, blurred vision, CNS effects (eg, anxiety, insomnia, restlessness, nervousness, palpitations, tremors, confusion, excitement, nightmares, ataxia, alterations in EEG patterns), edema, rash, elevated prolactin levels, nausea, dizziness, headache, fatigue, weakness, excessive appetite, increased perspiration.
Formerly known under the brand name Asendin.
Tabs 25mg, 50mg, 100mg—100; 150mg—30
Sign Up for Free e-newsletters
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|